Seaport Therapeutics Secures $225M in Series B Funding for Innovative Neuropsychiatric Medicines

Seaport Therapeutics, a pioneering clinical-stage biopharmaceutical company dedicated to transforming neuropsychiatric medicine, has successfully raised $225 million in its latest funding round. This significant investment will accelerate the development of innovative therapeutic candidates aimed at addressing the pressing needs of patients living with neuropsychiatric disorders. With a strong focus on overcoming historical barriers in drug development, Seaport Therapeutics leverages its proprietary Glyph technology platform, which allows for oral bioavailability, bypassing first-pass metabolism, and minimizing hepatotoxicity and unwanted side effects. This breakthrough approach positions Seaport's pipeline of first and best-in-class medicines at the forefront of the biopharmaceutical industry. The company is helmed by an experienced team with a proven track record in bringing neuropsychiatric treatments—such as the innovative KarXT—through the development pipeline. Seaport’s mission is driven by a dedication to improving patient outcomes and is supported by a robust network of leading scientists and clinicians in the field. This funding round not only highlights investor confidence in Seaport Therapeutics' vision but also underscores the increasing demand for effective neuropsychiatric therapies amidst a healthcare landscape fraught with unmet needs. As the company advances its clinical programs, it aims to redefine approaches to treatment and bring much-needed hope to patients and their families. For more information about Seaport Therapeutics and its groundbreaking work, please visit www.seaporttx.com or follow us on X (formerly Twitter) @SeaportTx.